UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 363

Sortiert nach

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

Cellular signalling, 2014-09, Vol.26 (9), p.2016-2029

2014

Link zum Volltext

Verfügbarkeit prüfen

Small molecule allosteric modulators of phosphodiesterase 4

Handbook of experimental pharmacology, 2011 (204), p.167

2011

Link zum Volltext

Verfügbarkeit prüfen

New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration

Journal of molecular structure, 2024-01, Vol.1295, p.136719, Article 136719

2024

Link zum Volltext

Verfügbarkeit prüfen

Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial

Journal of the American Academy of Dermatology, 2022-03, Vol.86 (3), p.607-614

2022

Link zum Volltext

Verfügbarkeit prüfen

Facile synthesis of carbon-11-labeled sEH/PDE4 dual inhibitors as new potential PET agents for imaging of sEH/PDE4 enzymes in neuroinflammation

Bioorganic & medicinal chemistry letters, 2019-07, Vol.29 (13), p.1654-1659

2019

Link zum Volltext

Verfügbarkeit prüfen

The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs

Frontiers in immunology, 2022-01, Vol.12, p.797390-797390

2022

Link zum Volltext

Verfügbarkeit prüfen

Urinary liver‐type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone‐induced acute kidney injury

Nephrology (Carlton, Vic.), 2024-03, Vol.29 (3), p.117-125

2024

Link zum Volltext

Verfügbarkeit prüfen

The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s)

Biochemical journal, 2014-05, Vol.459 (3), p.539-550

2014

Link zum Volltext

Verfügbarkeit prüfen

UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy

Cellular signalling, 2015-05, Vol.27 (5), p.908-922

2015

Link zum Volltext

Verfügbarkeit prüfen

Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays

Biochemical journal, 2007-05, Vol.404 (1), p.71-80

2007

Link zum Volltext

Verfügbarkeit prüfen

Phosphodiesterase 4 Inhibition Impairs Cocaine-Induced Inhibitory Synaptic Plasticity and Conditioned Place Preference

Neuropsychopharmacology (New York, N.Y.), 2012-10, Vol.37 (11), p.2377-2387

2012

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of the Phosphodiesterase 4 (PDE4) Enzyme Reverses Memory Deficits Produced by Infusion of the MEK Inhibitor U0126 into the CA1 Subregion of the Rat Hippocampus

Neuropsychopharmacology (New York, N.Y.), 2004-08, Vol.29 (8), p.1432-1439

2004

Link zum Volltext

Verfügbarkeit prüfen

Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK

Biochemical journal, 2010-05, Vol.428 (1), p.55-65

2010

Link zum Volltext

Verfügbarkeit prüfen

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

Bioorganic & medicinal chemistry, 2011-11, Vol.19 (21), p.6356-6374

2011

Link zum Volltext

Verfügbarkeit prüfen

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2016-08, Vol.16, p.S67-S73

2016

Link zum Volltext

Verfügbarkeit prüfen

The cardioprotective role of small heat-shock protein 20

Biochemical Society transactions, 2014-04, Vol.42 (2), p.270

2014

Link zum Volltext

Verfügbarkeit prüfen

ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity

International immunopharmacology, 2011-06, Vol.11 (6), p.732-739

2011

Link zum Volltext

Verfügbarkeit prüfen

PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects

Biochemical Society transactions, 2012-02, Vol.40 (1), p.210

2012

Link zum Volltext

Verfügbarkeit prüfen

Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor

International immunopharmacology, 2012, Vol.12 (1), p.50-58

2012

Link zum Volltext

Verfügbarkeit prüfen

Design, synthesis and in vitro PDE4 inhibition activity of certain quinazolinone derivatives for treatment of asthma

Medicinal chemistry research, 2012-11, Vol.21 (11), p.3327-3335

2012

Link zum Volltext

Verfügbarkeit prüfen

Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans

Biochemical pharmacology, 2004-12, Vol.68 (11), p.2229-2236

2004

Link zum Volltext

Verfügbarkeit prüfen

Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue

Biochemical journal, 2005-06, Vol.388 (Pt 3), p.803-811

2005

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E 2

Biochemical pharmacology, 2003-09, Vol.66 (5), p.801-807

2003

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity

Toxicologic pathology, 2006-01, Vol.34 (1), p.39-51

2006

Link zum Volltext

Verfügbarkeit prüfen

Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction

Cellular and molecular life sciences : CMLS, 2006-08, Vol.63 (15), p.1725-1735

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 363

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(356)
Mit Volltextzugriff
(336)

Publikationsform

Artikel
(359)
Buchkapitel
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(357)
Humans
(220)
Animals
(218)
Pharmacology & Pharmacy
(199)
Pde4
(182)
Cyclic Nucleotide Phosphodiesterases, Type 4 - Metabolism
(126)
Male
(113)
Cyclic Nucleotide Phosphodiesterases, Type 4
(106)
Phosphodiesterase 4 Inhibitors - Pharmacology
(100)
Rats
(99)
Chemistry, Medicinal
(93)
Biological And Medical Sciences
(91)
Medical Sciences
(82)
Chemistry
(77)
Physical Sciences
(77)
Phosphodiesterase Inhibitors - Pharmacology
(76)
Pharmacology. Drug Treatments
(74)
Phosphodiesterase
(74)
Mice
(72)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

Small molecule allosteric modulators of phosphodiesterase 4

New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration

Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial

Facile synthesis of carbon-11-labeled sEH/PDE4 dual inhibitors as new potential PET agents for imaging of sEH/PDE4 enzymes in neuroinflammation

The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs

Urinary liver‐type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone‐induced acute kidney injury

The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s)

UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy

Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays

Phosphodiesterase 4 Inhibition Impairs Cocaine-Induced Inhibitory Synaptic Plasticity and Conditioned Place Preference

Inhibition of the Phosphodiesterase 4 (PDE4) Enzyme Reverses Memory Deficits Produced by Infusion of the MEK Inhibitor U0126 into the CA1 Subregion of the Rat Hippocampus

Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

The cardioprotective role of small heat-shock protein 20

ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity

PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects

Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor

Design, synthesis and in vitro PDE4 inhibition activity of certain quinazolinone derivatives for treatment of asthma

Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans

Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue

Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E 2

Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity

Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction

Aktive Filter

Suchergebnisse filtern